Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2020 Apr;9(8):2812-2819.
doi: 10.1002/cam4.2933. Epub 2020 Feb 26.

Sequential boost of intensity-modulated radiotherapy with chemotherapy for inoperable esophageal squamous cell carcinoma: A prospective phase II study

Xing-Wen Fan  1   2 , Hong-Bing Wang  1   2 , Jing-Fang Mao  1   2 , Ling Li  1   2 , Kai-Liang Wu  1   2
Affiliations
Clinical Trial

Sequential boost of intensity-modulated radiotherapy with chemotherapy for inoperable esophageal squamous cell carcinoma: A prospective phase II study

Xing-Wen Fan et al. Cancer Med. 2020 Apr.

Abstract

Purpose: This prospective phase II study aimed to determine the efficacy and tolerability of sequential boost of intensity-modulated radiation therapy (IMRT) with chemotherapy for patients with inoperable esophageal squamous cell carcinoma (ESCC).

Methods: Patients with histologically or cytologically proven inoperable ESCC were enrolled in this study (ChiCTR-OIC-17010485). A larger target volume for subclinical lesion was irradiated with 50 Gy, and then, a smaller target volume only including gross tumor was boosted to 66 Gy. The fraction dose was 2 Gy, and no elective node was irradiated. Concurrent and consolidation chemotherapy of fluorouracil (600 mg/m2 , days 1-3) plus cisplatin (25 mg/m2 , days 1-3) was administered every 4 weeks, for 4 cycles in total. The primary endpoint was 2-year progression-free survival (PFS).

Results: Eighty-eight patients were enrolled in this study. The median age was 65 years (range: 45-75 years), and 69 patients (78.4%) were men. With the median follow-up of 26 (range: 3-95) months, the 2- and 5-year PFS were 39.3% and 36.9%, respectively, and overall survival (OS) were 57.1% and 39.2%, respectively. Tumor stage and concurrent chemotherapy were independent OS predictors. Major acute adverse events were myelosuppression and esophagitis, most of which were grades 1-2. Nine percent and 2.3% of patients had grade 3 acute esophagitis and late esophageal strictures, respectively.

Conclusions: Sequential boost to 66 Gy by IMRT with chemotherapy was safe and effective for inoperable ESCC. A randomized phase III study to compare with standard dose of 50 Gy is warranted.

Keywords: chemoradiotherapy; esophageal squamous cell carcinoma; intensity-modulated radiotherapy.

PubMed Disclaimer

Conflict of interest statement

No authors declare conflicts of interest.

Figures

Figure 1
Figure 1
The survival of 88 esophageal cancer patients. (A) progression‐free survival. (B) overall survival
Figure 2
Figure 2
Survival and relapse according to concurrent chemotherapy. (A) progression‐free survival. (B) overall survival. (C) local‐regional recurrence. (D) distant metastasis
Figure 3
Figure 3
One example for lymph node recurrence outside the PTV. (A) pretreatment, the short diameter of subcarinal lymph node (orange arrow) was 6 mm. (B) the radiotherapy target and radiation dose coverage. The subcarinal lymph node was out of plan tumor volume (PTV). Red area, gross tumor volume; blue area, PTV‐2; green area, PTV‐1; purple line, radiation dose of 66 Gy; yellow line, radiation dose of 50 Gy. (C) the volume of subcarinal lymph node (orange arrow) increased significantly 3 months after radiotherapy
See this image and copyright information in PMC

References

    1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68:394‐424. - PubMed
    1. Bollschweiler E, Metzger R, Drebber U, et al. Histological type of esophageal cancer might affect response to neo‐adjuvant radiochemotherapy and subsequent prognosis. Ann Oncol. 2009;20:231‐238. - PubMed
    1. Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA Cancer J Clin. 2014;64:9‐29. - PubMed
    1. Pennathur A, Gibson MK, Jobe BA, Luketich JD. Oesophageal carcinoma. Lancet. 2013;381:400‐412. - PubMed
    1. Cooper JS, Guo MD, Herskovic A, et al. Chemoradiotherapy of locally advanced esophageal cancer: long‐term follow‐up of a prospective randomized trial (RTOG 85–01) radiation therapy oncology group. JAMA. 1999;281:1623‐1627. - PubMed

Publication types